“…The potent soluble activators of FZD3/6/7 are very likely those ligands to be found overexpressed in HCCs (WNT3/4/5A). These data correlate with FZD3/6 and WNT3 found overexpressed in other malignancies as leukaemia, FZD7 in solid tumours like nasopharynx, oesophagus, and stomach carcinomas, WNT5A in leukaemia, melanoma, and nasopharynx carcinoma (Tanaka et al, 1998;Kirikoshi et al, 2001;Holcombe et al, 2002;Weeraratna et al, 2002;Qiang et al, 2003;Lu et al, 2004;Zeng ZY et al, 2007), whereas WNT4 has been previously found overexpressed in pancreatic cancers (Pasca di Magliano et al, 2007). Concerning the soluble activators of FZD, previous studies have shown the common downregulation of sFRP1 due to promoter hypermethylation in HCC as well as in colon cancer (Suzuki et al, 2004;Shih et al, 2006Shih et al, , 2007.…”